


[首页](#)
[最新一期](#)
[期刊动态](#)
[过刊浏览](#)
[医学视频](#)
[在线投稿](#)
[期刊检索](#)
[期刊订阅](#)
[合作科室](#)
[注册](#)
[登录](#)

您的位置: [首页](#)>> [文章摘要](#)

[中文](#) [English](#)

### 三阴性乳腺癌预后因素研究进展

周晓倩, 李想, 金慧, 刘俊

201620 上海市第一人民医院普外科

刘俊, Email: 15300795039@163.com

**摘要:**三阴性乳腺癌(TNBC)是乳腺癌的一个特殊亚型,具有侵袭性强、预后差、治疗方法单一等预后因素并用于指导TNBC的治疗具有重要临床意义。目前,研究较成熟的一些因素包括淋巴结状预后有关。淋巴结转移即预示着其较差的预后,但淋巴结转移数目的增加可能并不影响其预后;而预后越差。化疗及放疗是其主要的治疗方法,在不同程度上影响TNBC患者的预后。目前TNBC预后淋巴瘤/白血病-2(Bcl2)、p53蛋白(P53)、血管内皮生长因子(VEGF)及表皮生长因子受体(EGFR)等疗的反应。

**关键词:**乳腺肿瘤; 预后; 病理学, 临床; 治疗; 生物学标记

[评论](#) [收藏](#) [全](#)

文献标引:周晓倩, 李想, 金慧, 刘俊. 三阴性乳腺癌预后因素研究进展[J/CD]. 中华临床医师杂志: 电子版

[复制](#)

参考文献:

[1] Hortobagyi GN, de la Garza SJ, Pritchard K, et al. The global breast cancer in epidemiology and survival[J]. Clin Breast Cancer, 2005, 6(5): 391-401.

[2] Coughlin SS, Ekwueme DU. Breast cancer as a global health concern[J]. Cancer (5): 315-318.

[3] WHO. Globocan 2008: Estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide in 2008. 2nd January 2013[OL]. Available from: <http://g> (22 February 2013, date last accessed).

[4] Ossovskaya V, Wang Y, Budoff A, et al. Exploring molecular pathways of triple negative breast cancer[J]. Genes Cancer, 2011, 2(9): 870-879.

[5] Autier P, Boniol M, La Vecchia C, et al. Disparities in breast cancer mortality in 30 European countries: retrospective trend analysis of WHO[J]. BMJ, 2010, 341: c362.

[6] Vona-Davis L, Rose DP, Hazard H, et al. Triple-negative breast cancer and ob

期刊导读

8卷23期 2014年12月 [最新]



期刊存档

期刊存档

[查看目录](#)

期刊订阅



在线订阅



邮件订阅



RSS

作者中心



资质及晋升信息



作者查稿



写作技巧



投稿方式



作者指南

## 编委会

期刊服务



建议我们



会员服务



广告合作



继续教育

[7] Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival: a Breast Cancer Study[J]. *JAMA*, 2006, 295(21): 2492-2502.

[8] Rakha EA, El-Rehim DA, Paish C, et al. Basal phenotype identifies a poor prognostic breast cancer of clinical importance[J]. *Eur J Cancer*, 2006, 42(18): 3149-3156.

[9] Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network[J]. *Cancer*, 2012, 118(22): 5463-5472.

[10] Viviana B, Pietro S, Domenico G. Prognostic Impact of Triple Negative Phenotype in Conservatively Treated Breast Cancer[J]. *Breast J*, 2011, 17(4): 377-382.

[11] Lee JA, Kim KI, Bae JW, et al. Triple negative breast cancer in Korea-distribution and different impact of prognostic factors on survival[J]. *Breast Cancer Res Treat*, 2010, 122(1-2): 171-178.

[12] Dent R, Hanna WM, Trudeau M, et al. Pattern of metastatic spread in triple-negative breast cancer[J]. *Breast Cancer Res Treat*, 2009, 115(2): 423-428.

[13] Pogoda K, Niwińska A, Murawska M, et al. Analysis of pattern, time and risk factors of recurrence in triple-negative breast cancer patients[J]. *Med Oncol*, 2013, 30(1): 388-393.

[14] Hernandez-Aya LF, Chavez-MacGregor M, Lei X, et al. Nodal status and clinical outcome in a large cohort of patients with triple-negative breast cancer[J]. *J Clin Oncol*, 2011, 29(15): 2000-2006.

[15] Weigeh B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiles to breast cancer classification, prognostication and prediction: a retrospective of the last decade[J]. *Breast*, 2010, 220(2): 263-280.

[16] Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: a comparison between basal and nonbasal subtypes[J]. *Clin Cancer Res*, 2009, 15(7): 2302-2310.

[17] Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer[J]. *N Engl J Med*, 2010, 363(20): 1938-1948.

[18] 梁奋莉, 曹伟, 李林瑞, 等. 三阴性乳腺癌临床病理特点及预后因素分析[J]. *现代肿瘤学*, 2014, 20(3): 294-298.

[19] Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and clinical outcome in 740 breast cancer cases[J]. *Cancer*, 1989, 63(1): 181-187.

[20] Steward L, Conant L, Gao F, et al. Predictive Factors and Patterns of Recurrence in Women with Triple Negative Breast Cancer[J]. *Ann Surg Oncol*, 2014, 21(7): 2165-2171.

[21] Foulkes WD, Grainge MJ, Rakha EA, et al. Tumor size is an unreliable predictor of outcome in basal-like breast cancers and does not correlate closely with lymph node status[J]. *Breast Cancer Res Treat*, 2009, 117(1): 199-204.

[22] Schwentner L, Wolters R, Wischnowsky M, et al. Triple-negative breast cancer: impact of guideline-adherent adjuvant treatment on the cumulative survival—a retrospective multi-center analysis[J]. *Breast Cancer Res Treat*, 2014, 146(1-2): 171-178.

study[J]. Breast Cancer Res Treat, 2012, 132(3): 1073-1080.

[23] Rocca AI, Bravaccini S, Scarpi E, et al. Benefit from anthracyclines in r biological profiles in early breast cancer [J]. Breast Cancer Res Treat, 2014, 144(2)

[24] Tawfik K, Kimler BF, Davis MK, et al. Prognostic significance of Bcl-2 in i carcinomas: a comparative clinicopathologic study between "triple-negative" and non-tumors[J]. Hum Pathol, 2012, 43(1): 23-30.

[25] Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and patients with triple-negative breast cancer[J]. J Clin Oncol, 2008; 26(8): 1275-1281

[26] Martín M, Rodríguez-Lescure A, Ruiz A, et al. Molecular predictors of effic weekly paclitaxel in early breast cancer[J]. Breast Cancer Res Treat, 2010, 123(1):

[27] Dragun AE, Pan J, Rai SN, et al. Locoregional recurrence in patients with breast cancer: preliminary results of a single institution study[J]. Am J Clin Oncol. 237.

[28] Wang J, Shi M, Ling R, et al. Adjuvant chemotherapy and radiotherapy in tri carcinoma: a prospective randomized controlled multi-center trial[J]. Radiother Onco 200-204 .

[29] Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy w radiation therapy compared with breast-conserving therapy[J]. J Clin Oncol 2011, 29(

[30] Steward LT, Gao F, Taylor MA, et al. Impact of radiation therapy on survival triple-negative breast cancer[J]. Oncol Lett, 2014, 7(2): 548-552.

[31] Abdel-Fatah TMA, Perry C, Dickinson P, et al. Bcl2 is an independent progn triple negative breast cancer (TNBC) and predicts response to anthracycline combinat chemotherapy (CT) in adjuvant and neoadjuvant settings[J]. Ann Oncol, 2013, 24(11):

[32] Tawfik K, Kimler BF, Davis MK, et al. Prognostic significance of Bcl-2 in i carcinomas: a comparative clinicopathologic study between "triple-negative" and non-tumors[J]. Hum Pathol, 2012, 43(1): 23-30.

[33] 彭浩, 杨华伟, 宋立伟. 应用基因芯片技术筛选乳腺癌阿霉素耐药相关基因表达谱[J] 2009, 89(25): 1745-1748.

[34] Chae BJ, Bae JS, Lee A, et al. P53 as a specific prognostic factor in tripl cancer[J]. Jpn J Clin Oncol, 2009, 39(4): 217-224.

[35] Biganzoli E, Coradini D, Ambrogi F, et al. P53 status identifies two subgro negative breast cancers with distinct biological features[J]. Jpn J Clin Oncol, 2011

[36] Dumay A, Feugeas JP, Wittmer E, et al. Distinct TP53 mutants in breast can Int J Cancer, 2013, 132(5): 1227-1231.

[37] Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectru negative breast cancers[J]. Nature, 2012, 486(7403): 395-399.

[38] Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant Cisplatin in primary negative breast cancer[J]. J Clin Oncol, 2010, 28(7): 1145-1153.

[39] Linderholm BK, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary negative breast cancer[J]. Ann Oncol, 2009, 20(10): 1639-1646.

[40] Taha FM, Zeeneldin AA, Helal AM, et al. Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer[J]. Clin Biomed Res, 2013, 13(14): 1420-1426.

[41] Linderholm BK, Lindahl T, Holmberg L, et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer[J]. Cancer, 2008, 113(10): 2256-2260.

[42] Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by gene expression has superior prognostic value than triple-negative phenotype[J]. Clin Cancer Res, 2008, 14(22): 7623-7634.

[43] Zhang M, Zhang X, Zhao S, et al. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients[J]. Targ Oncol, 2013, 8(12): 1203-1210.

[44] Kosaka T, Yamaki E, Mogi A, et al. Mechanisms of resistance to EGFR-TKIs and development of a new generation of drugs in nonsmall-cell lung cancer[J]. J Biomed Biotechnol, 2011, 2011: 117423.

[45] Zhang X, Chang A. Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer[J]. Int J Med Sci, 2008, 5(4): 209-217.

## 综 述

### 胰高血糖素样肽-1及其受体激动剂对2型糖尿病患者体重减轻和心血管保护的作用

李意, 祝开思. .中华临床医师杂志: 电子版

2014;8(15):2833-2836.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

### 转移性非小细胞肺癌的放射治疗进展

李重, 黎静. .中华临床医师杂志: 电子版

2014;8(15):2837-2841.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

### 凋亡抑制基因Survivin的研究进展

曲贝贝, 左金华. .中华临床医师杂志: 电子版

2014;8(15):2842-2846.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

### NLRP6的研究进展

温哲, 唐朝晖. .中华临床医师杂志: 电子版

2014;8(15):2847-2851.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

### 骨骼肌活检在中枢神经变性疾病中的诊断作用

陈峥, 陈慧敏, 应可明, 王康军, 李定安. .中华临床医师杂志: 电子版

2014;8(15):2852-2856.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[精神分裂症与糖尿病共病流行病学、临床特征及发病机制新进展](#)

范毅敏, 杨程青, 胡国芹. .中华临床医师杂志: 电子版

2014;8(15):2857-2860.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[甘胆酸检测在肝胆疾病临床诊断中的意义](#)

王微, 虞留明, 朱学源. .中华临床医师杂志: 电子版

2014;8(15):2861-2865.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[甲状腺结节的诊疗进展](#)

赵军玉, 董建军, 姚金铭, 刘萌, 邵丽辉, 廖琳. .中华临床医师杂志: 电子版

2014;8(15):2866-2870.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[三阴性乳腺癌预后因素研究进展](#)

周晓倩, 李想, 金慧, 刘俊. .中华临床医师杂志: 电子版

2014;8(15):2871-2875.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[眼部术后干眼的发生机制与防护](#)

吕菊玲, 王兰, 吴菊芬, 张杰. .中华临床医师杂志: 电子版

2014;8(15):2876-2879.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[功能性消化不良病理生理机制研究进展](#)

赵丹, 毛华. .中华临床医师杂志: 电子版

2014;8(15):2880-2882.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[西罗莫司靶蛋白信号通路及认知功能障碍](#)

张苏云, 吴洁. .中华临床医师杂志: 电子版

2014;8(15):2883-2888.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[细胞因子诱导的杀伤细胞治疗肿瘤的研究进展](#)

庞佳楠, 崔久嵬. .中华临床医师杂志: 电子版

2014;8(15):2889-2893.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[| 编委会](#) [| 联系我们](#) [| 合作伙伴](#) [| 友情链接](#) [|](#)

© 2014版权声明 中华临床医师杂志(电子版)编辑部  
网站建设: 北京华夏世通信息技术有限公司 京ICP备0

北京市公安局西城分局备案编号: 110102000676